CRISPR Therapeutics AG (NASDAQ:CRSP) and Immunomedics Inc. (NASDAQ:IMMU) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||52||0.00||34.37M||-3.74||0.00|
Table 1 highlights CRISPR Therapeutics AG and Immunomedics Inc.’s gross revenue, earnings per share and valuation.
Table 2 has CRISPR Therapeutics AG and Immunomedics Inc.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||66,556,932.61%||-50.9%||-39.8%|
In next table is delivered CRISPR Therapeutics AG and Immunomedics Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||4||3.00|
CRISPR Therapeutics AG has a -9.07% downside potential and an average price target of $66.5. Meanwhile, Immunomedics Inc.’s average price target is $24.67, while its potential upside is 29.84%. Based on the results delivered earlier, Immunomedics Inc. is looking more favorable than CRISPR Therapeutics AG, analysts opinion.
Insider & Institutional Ownership
Roughly 50% of CRISPR Therapeutics AG shares are held by institutional investors while 95.3% of Immunomedics Inc. are owned by institutional investors. 2% are CRISPR Therapeutics AG’s share held by insiders. Competitively, Immunomedics Inc. has 7.19% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year CRISPR Therapeutics AG was more bullish than Immunomedics Inc.
CRISPR Therapeutics AG beats on 6 of the 11 factors Immunomedics Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.